Interferon-alpha and combined with ribavirin in HCV liver transplant recipients: Efficacy and predictors of response
VR Cicinnati, CG Klein, S Iacob, H Baba, G Sotiropoulos, P Hilgard, Y Erim, CE Broelsch, G Gerken, S Beckebaum · Zeitschrift für Gastroenterologie · 2007 · Heft 01
Bibliografische Angaben
Zusammenfassung
Optimal dose, duration and timing of antiviral treatment of hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) have not been established yet. The identification of factors predictive of response to interferon (IFN) treatment remains a crucial issue in the liver transplant setting. In this prospective study, 26 OLT patients were treated with standard interferon-alpha (IFN-alpha)–2b (2 MU daily) for 12 months or standard IFN-alpha–2b for 3 months followed by pegylated IFN (PEG-IFN)-alpha–2b (1.5 mcg/kg/week) for 9 months. IFN was combined with ribavirin (10–12mg/kg/day) in all patients…
